What do we know about atypical fractures in patients on bisphosphonates treatment? A literature review using a case series

Geriatric falls and risk factors

“…The absolute risk varies between 3.2-100 cases per 100,000 person-years, strongly depending on the duration of bisphosphonate therapy [84,85,88]. Bone healing is often delayed or failed in approximately 30% of these patients [87,89,90]. Thus, in harmony with the FDA recommendations, interruption and evaluation of bisphosphonates therapy is suggested after 3 years of continuous administration.…”